WORKSHOP DAY - TUESDAY OCTOBER 13, 2020
9am - 12pm EDT | 6am - 9am PDT
Understanding the Biomarker Profile
9:00 am - 12:00 pm
Being able to have deep insights in the biomarker profile is integral in drug development. Insights into the interactions of the complement system with the rest of the immune system and disease indication can help determine which biomarker to focus on. Both immune oriented biomarkers and surrogate markers can help drive the field forward by providing immune insights where complement such as upon the other parts of the immune system.
This workshop will discuss:
- How we leverage translational biomarker to accelerate development of complement directed therapies?
- How do you determine involvement of the separate pathways?
- Extrinsic pathway – how do you assess direct activation of C5, C5a, C3, C3a and how much comes from the actual pathway versus direct
- As complement therapies gain momentum in both rare and common disease, is it possible to pause treatments and watch if the disease comes back and how do you determine which biomarker to monitor for? Are there any pre-cursors to the development of a disease which can be monitored before the disease takes hold of a patient?
- What explanatory biomarker data is available that helps to understand the biology and our impact on the biology of the complement system?
- How can you measure the change in complement factors?
- Are there other interesting biomarkers that one could look at to understand complement activations beyond just components of the primary cascade?
- Are there any downstream marker that one could measure in a biomarker that could inform us something about a disease mechanism
Instructor in Medicine
Harvard Medical School